UMIN ID: UMIN000054709
Registered date:19/06/2024
Survey on the International Staging System and Chromosome Analysis Test in Multiple Myeloma Therapy
Basic Information
| Recruitment status | Pending |
|---|---|
| Health condition(s) or Problem(s) studied | Multiple Myeloma |
| Date of first enrollment | 2024/07/01 |
| Target sample size | 150 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | To grasp current use of the international staging system in multiple myeloma (MM) and describe the awareness and use of the newly established R2-ISS. 1_Current use of each international staging system 2_Thoughts on international staging system 3_Awareness of R2-ISS 4_Current use of R2-ISS 5_Intension to use R2-ISS and the reasons |
|---|---|
| Secondary Outcome | I. To describe the thoughts on and issues with the chromosome analysis test for MM treatment and the current measurement of 1q21gain/amplification. II. To clarify the prospect for the chromosome analysis test as a prognostic factor in the future 1_Current use of chromosome analysis test 2_Thoughts on and issues with the chromosome analysis test 3_Current measurement of 1q21gain/amplification 4_How the 1q21gain/amplification result is used 5_Thoughts on 1q21gain/amplification measurement |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Not applicable |
Related Information
| Primary Sponsor | Sanofi K.K. |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Sanofi K.K. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Tomoyuki Kusaka |
| Address | NMF Shinjuku EAST Bldg., 10-5 Tomihisacho, Shinjuku-ku, Tokyo, Japan Japan 162-0067 |
| Telephone | 03-6709-9710 |
| HOR@ssri.com | |
| Affiliation | Social Survey Research Information Co., Ltd. Healthcare Business Intelligence Service Division |
| scientific contact | |
| Name | Heigoroh Shirai |
| Address | Tokyo Opera City Tower, 3-20- 2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan Japan |
| Telephone | 03-6301-3000 |
| Heigoroh.Shirai@sanofi.com | |
| Affiliation | Sanofi K.K. Oncology Medical in Specialty Care |